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Abstract: (1R,2R-Diaminocyclohexane)oxalatoplatinum(II) (oxaliplatin) is a third 
generation platinum anticancer compound that produces the same type of inter- and 
intrastrand DNA cross-links as cisplatin. In combination with 5-fluorouracil, oxaliplatin 
has been recently approved in Europe, Asia, and Latin America for the treatment of 
metastatic colorectal cancer. We present here the crystal structure of an oxaliplatin ad-
duct of a DNA dodecanucleotide duplex having the same sequence as that previously 
reported for cisplatin (Takahara, P. M.; Rosenzweig, A. C.; Frederick, C. A.; Lippard, S. J. 
Nature 1995, 377, 649-652). Pt-MAD data were used to solve this first X-ray structure of a 
platinated DNA duplex derived from an active platinum anticancer drug other than 
cisplatin. The overall geometry and crystal packing of the complex, refined to 2.4 Å reso-
lution, are similar to that of the cisplatin structure, despite the fact that the two mole-
cules crystallize in different space groups. The platinum atom of the {Pt(R,R-DACH)]2+ 
moiety forms a 1,2-intrastrand cross-link between two adjacent guanosine residues in 
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the sequence 5’-d(CCTCTGGTCTCC), bending the double helix by ~30° toward the ma-
jor groove. Both end-to-end and end-to-groove packing interactions occur in the crystal 
lattice. The latter occurs in the minor groove opposite the platinum cross-link. A novel 
feature of the present structure is the presence of a hydrogen bond between the pseudo-
equatorial NH hydrogen atom of the (R,R)-DACH ligand and the O6 atom of the 3’-G of 
the platinated d(GpG) lesion. This finding provides the first structural evidence for the 
importance of chirality in mediating the interaction between oxaliplatin and duplex 
DNA, calibrating previously published models used to explain the reactivity of 
enantiomerically pure vicinal diamine platinum complexes with DNA in solution. It also 
provides a new kind of chiral recognition between an enantiomerically pure metal com-
plex and the DNA double helix.  
  
Introduction 
cis-Diamminedichloroplatinum(II) 1 (cisplatin, Fig. 1) received FDA approval in 
1979 for use as an anticancer drug. Cisplatin is widely used and is especially effective 
against testicular, head, neck, non-small-cell lung, and cervical cancers.1 DNA is gener-
ally agreed to be the biological target of cisplatin,2,3 with the major adduct being a 1,2-
intrastrand cross-link between the N7 atoms of two adjacent purine residues, either 
d(GpG) or less frequently, d(ApG).4 X-ray structures of cisplatin bound to several differ-
ent DNA sequences have been reported, providing insight into the structural changes 
that occur upon platination. Initially, several short, single-stranded deoxynucleosides 
containing the cis-[Pt(NH3)2{d(pGpG)}] unit were examined. These structures exhibited 
 3
large dihedral angles of 76 to 87° between the two cisplatin modified guanine bases.5-7 
The first single crystal X-ray structure of double-stranded DNA harboring a well-
defined cisplatin adduct was reported in 1995.8,9 Cisplatin coordination forces the du-
plex to bend significantly towards the major groove without disrupting Watson-Crick 
base pairing. Hydrogen bonding occurs between the oxygen atom of the 5' phosphate 
group and an NH3 ligand on platinum. The main portion of the duplex, starting from 
the 5’ end, adopts the A-DNA conformation and there is a switch to B-form DNA of the 
3’ end. A recent analysis of the cisplatin 12-mer crystal structure with the program 
3DNA, using the zP parameter to delineate A- from B-DNA, reveals the A/B junction to 
be distributed over two base pair steps.10 The same cisplatin modified 12-mer was stud-
ied in solution by NMR spectroscopy,11 allowing comparisons to be made between the 
solid and solution structures. In the solution structure, the DNA duplex is considerably 
more bent, and the dihedral angle between the planes of the cross-linked guanine bases 
is also much larger. A second NMR structure containing a platinum complex having the 
N-oxide spin label ligand 4-amino-TEMPO, bound similarly to a DNA undecamer,12 
shows a conformational change of DNA neighboring the platinum coordination site 
from A-like to B-like DNA.  
The cytotoxicity of cisplatin most likely involves the interaction of certain cellular 
proteins with the cisplatin-modified DNA.13 The first X-ray crystal structure of a 
cisplatin-modified 16-mer duplex complexed with one such protein, domain A of the 
high mobility group (HMG) protein HMG-1, revealed that the protein interacts mainly 
with the minor groove of the DNA, which is widened and bent towards the major 
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groove.14 A novel feature of this protein-DNA complex is the intercalation of a phenyl-
alanine between the two cross-linked guanosine residues. Interestingly, the coordination 
geometry at platinum better resembles that in the cisplatin modified single-strand dinu-
cleotide d(pGpG) structures6,15 than the geometries observed in the solution structures 
or the 12-mer X-ray crystal structure. Recent NMR studies of a cisplatin-modified DNA 
9-mer concluded that the choice of DNA starting model used in NMR-restrained molec-
ular dynamics refinements was crucial in determining the geometry of the final mini-
mized structure.16  Only when the conformation of the sugar-phosphate backbone from 
the platinated 16-mer/HMG1 domain A crystal structure was used did the NMR data 
refine to a satisfactory result. Based on these results, the authors predicted that all 1,2-
intrastrand platinum modified duplexes containing a d(XG*G*) or d(XA*G*) sequence 
(X = C or T) would have a similar structure in solution, with the XN (N = A* or G*) base 
pair step having a large positive shift and slide.  
Although cisplatin (1) is a very effective anticancer drug, it has many undesirable 
side effects and inherent and acquired resistance reduces its clinical efficacy. A number 
of less toxic second generation compounds have been synthesized, most notably car-
boplatin 2 (Fig. 1).17 (1R,2R-Diaminocyclohexane)oxalatoplatinum(II) 3a (oxaliplatin, 
Fig. 1) is a third generation platinum compound18 that produces the same kind of inter- 
and intrastrand DNA cross-links as cisplatin.19 Oxaliplatin, in combination with 5-
fluorouracil, has been recently approved in Europe, Asia, and Latin America20 but not in 
the USA,15 for the treatment of metastatic colorectal cancer.  
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The stereochemistry of the 1,2-diaminocyclohexane moiety significantly influ-
ences the toxicity of the platinum complexes toward various cancer cell lines. Complex-
es of the two trans diastereomers (R,R and S,S) exhibit higher activities than the meso 
(R,S and S,R) adducts, and the (R,R) complex is more effective than the (S,S).21-24 Alt-
hough oxaliplatin forms fewer lesions than cisplatin, it is more cytotoxic against some 
cell lines.25 During replication, translesion synthesis catalyzed by DNA polymerases 
(pol) , , , and  is more efficient, but also more error prone, past oxaliplatin adducts 
than past cisplatin adducts.26,27 From a study of the kinetics of nucleotide insertion op-
posite Pt-GG adducts by mammalian pol , it was predicted that “the oxaliplatin and 
cisplatin-GG adduct will show the greatest conformational differences in the vicinity of 
the 3’-G(Pt)”.28 Furthermore, both HMG126 and its isolated HMG domains A and B 
demonstrate lower affinity for oxaliplatin-DNA adducts than the corresponding 
cisplatin lesions.29 
Little structural information exists for oxaliplatin DNA adducts. The complexes 
of (1R,2R)-diaminocyclohexane)platinum(II), (R,R)-DACH-Pt(II), with either two 
deoxyguanosine 5’-monophosphates30 or d(GpG)31 have been investigated by 1H-NMR 
spectroscopy. Molecular modeling studies of cisplatin or (R,R)-DACH-Pt(II) bound to a 
duplex dodecamer propose a geometry around the platinum atom of the oxaliplatin 
cross-link similar to that in the corresponding cisplatin structures.32 Only in the cisplatin 
model, however, was a hydrogen bond predicted to form between the 3’ amine to the 
carbonyl oxygen (O6) of the guanosine. It has been proposed that the hydrophobic cy-
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clohexane ring changes the overall DNA geometry, but there is no experimental confir-
mation of this hypothesis. 
Studies of (2R,3R)- and (2S,3S)-diaminobutane(DAB)platinum(II) complexes 
bound to natural DNA and synthetic oligodeoxyribonucleotide duplexes in a cell-free 
medium revealed the influence of the stereogenic centers of the ligand upon the overall 
geometry. Reaction of these DNA damaging agents indicated the DNA to be more dis-
torted on the 3’/5’ sides of the cross-link for the (R,R)-/(S,S)-DAB-Pt complexes, respec-
tively.33 These results support the notion that a hydrogen bond forms in solution be-
tween an amino group and the O6 atom of a coordinated guanine cis to that group. Such 
an interaction was observed in small molecule crystal structures containing the 
{PtN2(Gua)} moiety, where N is an achiral (di)amine and Gua a 6-oxo purine,34-37 as well 
in a molecular modeling study of a single-stranded platinated DNA.38 
Only duplex oligonucleotides containing cisplatin adducts have thus far been in-
vestigated by single crystal X-ray analysis. Furthermore, there exists no experimental 
structure of a lesion formed by oxaliplatin coordinated to double-stranded DNA. We 
report here the synthesis and crystallization of a 12-mer duplex DNA containing a 1,2-
d(GpG) oxaliplatin intrastrand cross-link (6) in a sequence identical to that in earlier 
cisplatin-modified DNA structures (Figure 2).8,9,11 The structure affords deeper insights 
into the differences between cisplatin and oxaliplatin, a molecular level view of the dif-
ferent interactions of the enantiomers of trans-vicinal diamino ligands with DNA, and 
some commonality of the overall structures of platinated DNA lesions determined pre-
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viously. These findings should aid further investigations into the design of better plati-
num antitumor drugs. 
 
Experimental Section 
Materials. (1R,2R)-Diaminocyclohexane was obtained from Aldrich and potassi-
um tetrachloroplatinate(II), K2PtCl4, was provided by Johnson-Matthey. 
Phosphoramidites and reagents for DNA synthesis were purchased from Glen Research. 
Crystallization reagents were obtained from Aldrich, Fluka, Mallinckrodt, and Sigma.  
High-pressure liquid chromatography (HPLC) was carried out on a Waters 600E 
system controller with a Waters 486 detector ( = 260 nm) for preparative runs or on a 
Waters 600S controller and Waters 2487 detector ( = 260 nm) for analytical runs. Atom-
ic absorption spectroscopy was performed using a Varian AA1475 instrument. 
Synthesis and Characterization of (1R,2R)-Diaminocyclohexanedichloro-
platinum(II) (3b). (1R,2R)-Diaminocyclohexanedichloroplatinum(II) (3b) was prepared 
from (1R,2R)-diaminocyclohexane and potassium tetrachloroplatinate(II) in 82% yield as 
described.21 It was fully characterized by 1H-,13C-, and 195Pt-NMR spectroscopy (see 
Supporting Information). Slow evaporation from DMF yielded colorless crystals of 
3bDMF after one month, which were suitable for X-ray analysis. The crystal structure 
determination was carried out on a Bruker (formerly Siemens) CCD diffractometer with 
graphite-monochromatized Mo K radiation (= 0.71073 Å) controlled by a Pentium-
based PC running the SMART software package.39 Single crystals were mounted at 
room temperature on the ends of glass fibers in Paratone N oil, and data were collected 
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for 20 seconds per frame at 188 K in a stream of cold dinitrogen maintained by a Bruker 
LT-2A nitrogen cryostat. Data collection and reduction protocols are described in detail 
elsewhere.40 The structure was solved by direct methods and refined using the 
SHELXL97 software package.41 Hydrogen atoms were assigned idealized locations. 
Empirical absorption corrections were applied by using SADABS.42 Relevant crystallo-
graphic information is given in Figure S1 and Tables S1-S4. 
Deoxyoligonucleotide Synthesis and Purification. Figure 2 shows three single-
stranded DNAs that were prepared according to procedures reported previously.9 The 
deoxyoligonucleotides were synthesized on a 10 mol scale with an Applied Biosystems 
392 DNA/RNA automated synthesizer by using conventional phosphoramidite solid 
support methodology.43 Protecting groups were removed by G25 Sephadex size exclu-
sion chromatography. The top strand, to be platinated, was passed through an ion ex-
change DOWEX column in order to replace the ammonium by sodium ions, since the 
former might react with platinum in a subsequent step. 
A 21 mM aqueous solution of (1R,2R)-diaminocyclohexane platinum(II) dichlo-
ride (3b) was activated by treatment with 1.98 equiv of silver nitrate and agitation over-
night in the dark. The suspension was centrifuged, and the mother liquor transferred to 
another vial and centrifuged again. A 1.1 equivalent portion of the solution containing 
the activated (R,R)-DACH-Pt(II) was added to 10 mL of a 0.414 mM (4.14 mol) aqueous 
solution of 4a. The reaction, carried out in the dark at 37 ºC, was complete in 90 min, as 
revealed by analytical ion exchange HPLC, and was terminated by freezing. The 
platinated product 4b and the complementary bottom strand 5 were purified on a pre-
 9
parative ion exchange HPLC column, eluting with a 150-300 mM linear NaCl gradient 
and subsequently with a 5-20% acetonitrile gradient on a preparative reverse phase C4 
HPLC column. 
A 0.998 mL aliquot of a 1.053 mM solution of the top strand 4b (1.05 mol) and 
0.263 mL of a 4.00 mM solution of the bottom strand 5 (1.05 mol) were annealed by 
mixing for 10 min at room temperature. The annealed double strand 6 was purified by a 
0.2 M to 0.5 M lithium chloride gradient on a preparative ion-exchange HPLC column to 
give 0.645 mol of 6 with an rb ratio of 0.986. A solution of 6 was divided into equal ali-
quots, each containing 240 g of DNA. The aliquots were heated to 80 ºC, allowed to 
cool to room temperature within 6 h, then cooled to 4 ºC for 1 h, and finally lyophilized 
and stored at –20 ºC. 
Crystallization of 6. The hanging drop vapor diffusion method was used for 
crystallization,44 starting with conditions from 2 different sparse matrix crystallization 
screens.45,46 Crystals were grown at 4 ºC from 3.0 L drops containing 0.2 mM DNA, 2.5 
or 5% MPD ((±)-2-methyl-2,4-pentanediol), 20 mM sodium cacodylate (pH 7.0), 6 mM 
spermine4HCl, 10 mM barium dichloride, and 2.5% ethyl acetate equilibrated against a 
reservoir of 20 or 30% MPD and 5% ethyl acetate. Crystals with maximum dimensions 
of 0.08  0.2  0.4 mm3 appeared after 5 days. 
X-ray Data Collection of 6. Crystals were transferred to a solution of 30% MPD, 
40 mM sodium cacodylate (pH 7.0), 12 mM spermine4HCl, 20 mM barium dichloride, 
and 5% ethyl acetate at 4 °C, then mounted in loops and flash frozen. Multiwavelength 
anomalous diffraction (MAD) studies47 using 6 were conducted at 100 K on beamline 
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19-ID of the Structural Biology Center-CAT at the Advanced Photon Source at Argonne 
National Laboratory. The platinum absorption spectrum was measured as X-ray fluo-
rescence using a Bicron scintillation counter. The values of f’ and f” were calculated with 
the program CHOOCH.48 Four wavelengths were selected for data collection corre-
sponding to the inflection point (1.0724 Å), the peak (1.0721 Å), and two remote energies 
(1.0277 Å, 1.1206 Å) with respect to the absorption edge of platinum. Complete data sets 
were collected successively for each wavelength on the SBC APS1 3x3 CCD detector. 
Each data set required approximately 12 min to collect (100 frames, 1º each, 4 s/frame). 
Intensities were integrated using DENZO and scaled with SCALEPACK.49 
Subsequently, data from a crystal of 6 grown under lower MPD concentrations 
were collected at beamline 9-1 of the Stanford Synchrotron Radiation Laboratory (wave-
length 0.970 Å, Mar Research imaging plate detector, 100 frames, 2º each, 32 s/frame) to 
2.4 Å resolution and processed with the HKL suite of programs.49 Data collection statis-
tics are summarized in Table 1. 
Structure Determination and Refinement of 6. MAD phases were calculated by 
using the program CNS (v 1.0) for the space groups I222 and I212121.50 After solvent flat-
tening, only the phase information for I222 produced a readily interpretable electron 
density map (Figure 3). An initial model was then subjected to rigid body refinement.50 
Data to 2.8 Å resolution were used for cycles of positional, simulated-annealing, and B-
factor refinements, interspersed with analysis of the geometry of the model. A peak of 
high electron density found at a distance of 2.6 Å to N7 of G31 was modeled as a fully 
occupied barium ion. 10% of the initial reflections were set aside for use in calculating 
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Rfree.51-53 Manual model rebuilding was performed in O.54 Phases from a model with 
Rfree = 32.7% and R = 29.5 % were applied for a similar series of refinement cycles using 
the 2.4 Å data set. Refinements were completed by using a slightly modified program 
version of SHELXL9741 in which the HOPE parameter55 was set to neutral if it became 
negative for some reflections during the refinement. The DNA Dictionary for SHELXL 
was used with the appropriate restraints for the phosphodiester backbone, sugars and 
nucleobases.56,57 The DACH ligand, bound to platinum, was refined with 1,2 and 1,3-
distance restraints. Twelve water molecules were added at locations having proper dis-
tance for hydrogen-bonding interactions and electron densities greater than 1.0  on a 
|2|Fo|-|Fc|| map and 2.0  on an ||Fo|-|Fc|| map. Except for the barium cation, no 
other counterions were found to be associated with the DNA backbone. Refinement sta-
tistics are given in Table 1. The geometry parameters were calculated with the programs 
3DNA,58 Curves,59 Freehelix,60 MacMoMo,61 MadBend,62 and PLATON.63  The atomic 
coordinates for the final, refined model have been deposited in the Nucleic Acid Data-
base with accession number DD0040 (PDB file number: 1IHH). 
 
Results 
X-Ray Structure of 3b. The structure of (1R,2R)-diaminocyclohexanedichloro-
platinum(II) (3b) is depicted in Figure 4. Crystallographic data for (3bDMF) are given in 
Table S1. The two molecules in the asymmetric unit have almost identical geometry. The 
platinum atoms are distorted square planar with adjacent angles between 83.6(2) and 
94.88(7)º. The cyclohexane rings have a typical chair conformation. 
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Unit Cell Composition and Crystal Packing of 6. The asymmetric unit contains 
one molecule of 6. The crystals have a Matthew’s coefficient of 2.82, corresponding to a 
solvent content of about 55%. There are two types of interactions between the duplexes 
in the lattice: end-to-end, produced by the diad perpendicular to the DNA axis, Figures 
3 and S4, and end-to-minor groove. Both interactions, mediated by several hydrogen 
bonds (see below), were also present in the structure of the cisplatin analogue.8,9 The 
end-to-end contact, typical for B-DNA,64 places the 3’ C12 base of one duplex stacked on 
the 5’ G21 of another, thereby forming a pseudo helix. In the end-to-minor groove inter-
action, the 5’ terminal base pair, C1-G32, packs against the minor groove opposite the 
platinum binding site of a neighboring duplex. Such a packing motif is often seen in A-
DNA,65 and is present in the cisplatin-DNA structure. In this interaction, the O3’ hy-
droxyl of G32 donates its hydrogen to O2 of T8 and O2 of C26. Twelve water molecules 
were located, forming hydrogen bonds to the DNA (see Figure S2). 
The Platinated DNA Duplex. The two strands maintain their hydrogen bond 
base pairing throughout the entire helix despite the coordination of platinum. The base 
pair parameters and sugar conformations are shown in Figure 5 and Table 2, respective-
ly. Additional base pair step parameters appear in Tables S5 – S8 and Figure S3 in the 
Supporting Information. The first seven base pair steps including C1 – G32 through T8 – 
A25 adopt an A-DNA-like conformation and the two last steps, T10 – A23 through C12 – 
G21, are very similar to B-DNA, judging by the slide, zp, sugar puckering, and mi-
nor/major groove parameters. In accord with a recent analysis of A-form motifs in lig-
and-bound DNA structures,10 we also find that the A/B junction is distributed over two 
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dimer steps, between the base pairs T8 – A25 and T10 – A23. As seen in the previous 
structural determination of cisplatin-modified DNA, the minor groove is widened 
whereas the major groove has become even narrower than the minor groove (Table S9). 
The two planes of the nucleobases G6 and G7 form a dihedral angle of 25°. The pseudo-
equatorial hydrogen of the NH2 group of the DACH ligand cis to the N7 atom of gua-
nine G7 forms a hydrogen bond to oxygen O6 of G7 (N – O distance: 2.9 Å, angle of N – 
H  O: 136°, Figure 6). In the cisplatin analog, the corresponding N–O distance is 3.5 Å. 
The shortest distance between the other DACH amino nitrogen atom, cis to N7 of G6, 
and the oxygen atom of the next phosphate group in the 5’ direction is 4.6 Å. The dis-
tance of this atom to O6 of G6 is 4.4 Å. Both values are too long for hydrogen bond for-
mation. The platinum atom has a strongly distorted square-planar environment, with cis 
angles between the nitrogen donor atoms ranging from 80° to 98°. The platinum atom is 
displaced from the mean planes of G6 and G7 by 1.3 Å and 0.8 Å , respectively. 
Bend angle. The bend angles of DNA structures containing a 1,2-G,G intrastrand 
platinum cross-link, calculated with MadBend62 based on the local base pair steps from 
the various programs, are given in Table 3. Previously, the bend angles of platinum 
modified duplex DNA structures have always been calculated by taking the two axes 
defined by base pairs at the 5’ and 3’ ends of the helix and calculating the angle between 
the two lines projected onto a common plane. The recently published program 
MadBend allows one to calculate an overall bend angle by using local base pair step pa-
rameters. The calculated bend angles for various published structures of platinated 
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DNA vary greatly, however, depending on the program used to calculate the local base 
pair step parameters, as revealed by the results in Table 3. 
Barium Binding to N7 of G31. Barium is the only other cation located in the 
structure apart from platinum. It coordinates to N7 and O6 of G31 and forms a bridge to 
the adjacent purine base A30 by binding to N7 of this residue. A water molecule is the 
fourth ligand bound to the cation. We assign the geometry as a distorted octahedron, 
with angles ranging between 66° and 90°. Two missing ligands were not accounted for 
by the electron density. This example is the first in which a barium cation has been dis-
covered to bridge an adenine and a guanine, although Ba2+ links two guanines in an 
intrastrand manner in A-DNA66 and in an interstrand fashion in Z-DNA.67 
 
Discussion 
Structures of [Pt((R,R)-DACH)Cl2] and its DNA Adduct with 6. As indicated in 
Figure 4, the X-ray structure of [Pt((R,R)-DACH)Cl2] reveals a chelate ring in the 
gauche conformation, a geometry encountered previously in related (R,R)-DACH-Pt 
structures.68,69 Addition of the Ag+-activated form of 3b to 4a readily affords the desired 
site-specifically platinated dodecanucleotide 4b, and annealing to 5 leads to the 
oxaliplatin-modified DNA duplex 6. This species crystallized in space group I222 with 
one molecule in the asymmetric unit, compared to the cisplatin analog, which had two 
molecules per unit cell in space group P1. Only one other DNA structure has been re-
ported in space group I222.70  
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Despite the different space group and unit cell packing, the overall geometry of 6 
is similar to that of the cisplatin analog with respect to the helix bend angle, mainly A-
DNA conformation, and end-to-end and end-to-minor groove intermolecular DNA con-
tacts. The parameters of slide, zp, roll (Fig. 5), as well as rise, shift, and twist (Fig. S3), 
and are graphically displayed together with those for the 2 molecules of the cisplatin 
analogue (named TT12-1 and TT12-2) and for canonical A and B DNA duplexes. From 
these plots it is clear that the parameters for the roll, shift, slide, zp and, to a lesser extent, 
rise are all very similar. This similarity is also manifest by the low rmsd values, calculat-
ed for all common atoms, of 0.86 Å for 6 and molecule A (TT12-1) of the cisplatin-
dodecamer and 0.87 Å for 6 and molecule B (TT12-2). TT12-1 and TT12-2 themselves su-
perimpose with an rmsd value of 0.27 Å. 
Influence of the Chiral Ligand on Oxaliplatin Binding to DNA. The platinum 
oxalato complex containing the (1R,2R)-diaminocyclohexane ligand (oxaliplatin) is 
pharmacologically more potent than the (S,S)-enantiomer.22-24 Solution studies of 
(2R,3R)-diaminobutaneplatinum(II), {(R,R)-(DAB)-Pt}2+ complexes bound to duplex 
DNA suggest the presence of a hydrogen bond between the DAB nitrogen cis to the 3’-G 
of the GG lesion and the O6 of the 3’-guanine,33 mediated only by the pseudo equatorial 
hydrogen atom of the NH2 moiety. Such a feature has been observed previously in small 
molecule crystal structures of platinum(II) purine complexes containing achiral 
(di)amine ligands37 and in a molecular modeling study of a platinated, single-stranded 
DNA38. The results described here provide structural proof for such a hydrogen bond-
ing interaction between a chiral ligand in a Pt(II) complex with the chiral DNA molecule 
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to which it is coordinated (see Figure 6). Binding of the (R,R)-DACH or (R,R)-DAB lig-
and to platinum both locks the conformation of the C–N bond, thereby fixing the posi-
tion of the hydrogen atoms of the NH2 groups, and directs the pseudo equatorial hy-
drogen atom cis to the 3’-guanine to form a hydrogen bridge to the O6 of the [remove] 
nucleobase. Chaney et al. correlated the higher cytotoxicity of oxaliplatin with the great-
er degree of translesion synthesis by mammalian polymerase  past oxaliplatin.28 Such 
translesion synthesis induces mutations. The differences between the crystal structures 
of cisplatin and oxaliplatin bound to DNA reveal that only the latter has a hydrogen 
bond to the 3’ guanine. This result confirms the prediction by Chaney et al. that the 
oxaliplatin and cisplatin-GG adduct will show the greatest conformational differences in 
the vicinity of the 3’-G(Pt). 
A remaining question is whether the observed differences in cytotoxicity for the 
various configurational isomers of oxaliplatin are modulated by differentiating reactions 
that occur prior to attack on DNA and/or whether such reactions occur when proteins 
interact with platinum lesions on DNA, forming ternary complexes. 
 
Conclusion 
An (R,R)-DACH platinum(II) 1,2-intrastrand d(GpG) cross-link in a DNA duplex 
with the same sequence as that previously investigated for cisplatin was synthesized, 
purified, and crystallized. Pt-MAD data afforded the X-ray crystal structure of a non-
cisplatin complex with a platinated DNA duplex. The overall geometry is relatively sim-
ilar to that of the cisplatin-modified DNA, although the two adducts crystallize in two 
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different space groups. A hydrogen bond forms between the pseudo-equatorial NH of 
the (R,R)-DACH ligand and the O6 atom of the 3’-G of the d(GpG) lesion, affording ex-
perimental evidence for this kind of chiral interaction. The structure provides the first 
unambiguous evidence on a molecular level of how cisplatin and oxaliplatin differen-
tially modify DNA. This finding suggests that the search for a better anticancer drug 
might be directed toward the design of molecules that form hydrogen bonds directly to 
DNA in the vicinity of the platinum lesion. 
 
Acknowledgment. This work was supported by a grant from the National Can-
cer Institute. B. S. was supported by the Swiss National Science Foundation and the No-
vartis Foundation. We thank Prof. C. Drennan, Drs. Uta-Maria Ohndorf and Tzanko 
Doukov, and Mr. Mike Sintchak for helpful discussions, and Prof. George Sheldrick for 
providing us with a modified version of his SHELXL97 program. We thank Dr. Frank J. 
Rotella for helping us to acquire the Pt-MAD data at Argonne. Use of the Argonne Na-
tional Laboratory Structural Biology Center beamlines at the Advanced Photon Source, 
was supported by the U. S. Department of Energy, Office of Biological and Environmen-
tal Research, under Contract No. W-31-109-ENG-38. X-ray data were also collected at 
the Stanford Synchrotron Radiation Laboratory (SSRL), which is funded by the Depart-
ment of Energy (BES, BER) and the National Institutes of Health (NCRR, NIGMS).  
 
 18
Supporting Information Available: Spectroscopic and crystallographic infor-
mation for 3b and 6 (PDF) is available free of charge via the Internet at 
http://pubs.acs.org. 
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Table 1. Data Collection and Refinement Statistics for 6 
     high resolutionb 
Data collection 
wavelength [Å]  1.0721 1.0724 1.0277 1.1206 0.970 
a [Å] 42.492 42.500 42.490 42.501 41.942 
b [Å] 49.468 49.462 49.503 49.480 51.246 
c [Å] 85.639 85.614 85.491 85.605 87.049 
resolution range [Å] 25 - 2.8 25 - 2.8 25 - 2.8 25 - 2.8 100 – 2.4 
observed reflections 34 018 34 232 34 101 33 882 61 465 
unique reflections 2 371 2 369 2 369 2 365 6 296 
completenessc [%] 96.1 (76.4) 96.4 (80.8) 95.7 (73.4) 95.5 (72.0) 93.7 (69.0) 
Rsymc,d [%] 10.5 (42.9) 8.5 (46.1) 7.6 (46.4) 6.2 (51.5) 8.9 (36.8) 
<I/> c 19.1 (3.2) 35.6 (3.2) 35.6 (3.3) 35.3 (2.6) 18.9 (4.5) 
phasing powere 4.0 3.7 2.6 1.7  
Refinement 
Rf [4448 refl. with Fo > 4 (Fo)]     0.209 
Rfreeg [487 refl. with Fo > 4  (Fo)]     0.256 
rmsd bond lengths [Å]     0.007 
rmsd 1,3-distances (angles) [Å]     0.021 
rmsd planes (for 252 atoms) [Å]     0.0005 
no. of refined parameters     2052 
no. of restraints     2360 
 
a Crystals grown from 5% MPD solutions, measured at the SBC-19ID beamline at the Advanced Photon 
Source. b Crystals grown from 2.5% MPD solutions, measured at the beamline 9-1 at the Stanford Synchro-
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tron Radiation Laboratory. c Values in brackets for the highest resolution shell. d Rsym = |I - <I>|/I. e 
Phasing Power = [(Fh2)/(r.m.s. lack of closure)]0.5. fR = ||Fo|-|Fc||/|Fo|. gRfree = R obtained for a test 
set of reflections (10% of the diffraction data). 
Table 2. Sugar Conformational Parameters for 6  
Strand I    Strand II    
base tma 
[°] 
Pb [°] Pucker-
ing 
base tma 
[°] 
Pb [°] Puckering 
1 C 40.9 26.0 C3'-endo 1 G 38.7 340.2 C2'-exo  
2 C 34.7 25.0 C3'-endo 2 G 41.1 25.7 C3'-endo 
3 T 42.8 19.9 C3'-endo 3 A 39.3 19.1 C3'-endo 
4 C 41.0 23.3 C3'-endo 4 G 37.8 20.6 C3'-endo 
5 T 29.7 19.2 C3'-endo 5 A 50.9 43.1 C4'-exo  
6 G 37.2 39.5 C4'-exo  6 C 41.1 24.5 C3'-endo 
7 G 38.8 20.4 C3'-endo 7 C 38.5 19.9 C3'-endo 
8 T 36.2 32.8 C3'-endo 8 A 37.3 31.4 C3'-endo 
9 C 30.5 29.6 C3'-endo 9 G 48.2 146.1 C2'-endo 
10 T 22.8 123.5 C1'-exo  10 A 28.9 175.1 C2'-endo 
11 C 40.9 132.0 C1'-exo  11 G 49.4 170.9 C2'-endo 
12 C 38.0 69.6 C4'-exo  12 G 30.3 224.4 C4'-endo 
A-DNAc 42 18 C3'-endo A-DNAc 42 18 C3'-endo 
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B-DNAd 46 154 C2'-endo B-DNAd 46 154 C2'-endo 
a tm: amplitude of pseudorotation of the sugar ring. b P: phase angle of 
pseudorotation of the sugar ring. c see ref. 71. d see ref. 72. 
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Table 3. Structures of 1,2-platinated DNA models with a d(GpG) unit 
 
 
DNA model 
bend  bend  
(Curves, 
MadBend) 
bend  
(Freehelix, 
MadBend) 
bend  
(3DNA, 
MadBend) 
Guanine 
dihedral 
angles 
Pt displ. 
from G 
plane 
X-ray of 
d(pGpG)5 
n.a. n.a. n.a. n.a. 76º - 87º 0.2 Å, 5’ 
 0.4 Å, 3’ 
X-ray of 12mer8 ~39º and 55º 28º and 26º 24º and 26º 27º and 28º 28º 1.3 Å, 5’ 
 0.8 Å, 3’ 
NMR of 12mer11 ~ 78º 80º 52º 80º 49º 0.8 Å, 5’ 
 0.8 Å, 3’ 
X-ray of 16mer + 
HMG1 domA14 
~ 61º 43º 66º 47º 75º 0.5 Å, 5’ 
 0.2 Å, 3’ 
DACH 12mera  30º 24º 29º 25º 1.3 Å, 5’ 
 0.8 Å, 3’ 
a This work. 
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Figure Captions 
Figure 1. Structures of cisplatin (1), carboplatin (2), and (1R,2R)-
diaminocyclohexaneplatinum(II) (3) complexes including oxaliplatin (3a).  
Figure 2.  Oligonucleotide sequences used in this work. 
Figure 3. Solvent flattened initial electron density map of 6 using the 2.8 Å resolu-
tion data and showing the end-to-end intermolecular DNA stacking. 
Green color depicts the 1 contour level and purple, the 5 level. 
Figure 4. ORTEP plot of (1R,2R)-diaminocyclohexanedichloroplatinum(II) (3b) 
showing 50% probability thermal ellipsoids. 
Figure 5. Roll, slide and zp parameter for 6, TT12-1, and TT12-2;8,9 calculated with 
the program 3DNA.58  
Figure 6. Close-up of 6 showing the GG base pair step together with the bound Pt-
DACH complex. The nitrogen atom of the DACH ligand cis to N7 of G7 
forms a hydrogen bond to O6 of G7 via the pseudo equatorial hydrogen. 
Picture drawn with the programs Molscript73 and Raster3D.74 
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Figure 1, Spingler, Whittington, and Lippard
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5’- C1 C2 T3 C4 T5 G*6 G*7 T8 C9 T10 C11 C12 -3’ 4a 
 
              
H2N
Pt
NH2
 
5’- C1 C2 T3 C4 T5 G*6 G*7 T8 C9 T10 C11 C12 -3’ 4b 
               
3’- G32 G31 A30 G29 A28 C27 C26 A25 G24 A23 G22 G21 -5’ 5 
 
 
 
Figure 2, Spingler, Whittington, and Lippard 
}6 
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Figure 3, Spingler, Whittington, and Lippard 
 32
 
 
 
 
 
Figure 4, Spingler, Whittington, and Lippard 
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Figure 5, Spingler, Whittington, and Lippard 
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Figure 6, Spingler, Whittington, and Lippard 
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Synopsis: 
 
The 1,2-intrastrand complex of a duplex DNA 12-mer with the anticancer drug 
oxaliplatin was synthesized and crystallized. The crystal structure was solved by plati-
num MAD and refined to 2.4 Å resolution. The pseudo-equatorial hydrogen atom of the 
DACH ligand NH2 group cis to the N7 atom of guanine G7 forms a hydrogen bond to 
oxygen O6 of G7. The x-ray structure of the precursor (1R,2R-
diaminocyclohexane)dichloroplatinum(II) is also presented. 
 
 
 
